Table 1. Baseline Clinical and Demographic Features.
| Characteristic overall | No. (%) (N = 1193) | P valuea | |||
|---|---|---|---|---|---|
| GBA PD (n = 128) | LRRK2 PD (n = 155) | LRRK2/GBA PD (n = 21) | Idiopathic PD (n = 889) | ||
| Age, mean (SD) y | 64.4 (9.9) | 68.4 (9.2) | 65.7 (9.0) | 66.6 (10.0) | .006 |
| Age at PD onset, yb | 57.5 (10.2) | 60.1 (9.6) | 59.6 (9.9) | 61.1 (10.0) | .003 |
| Duration of PD, y | 6.9 (5.9) | 8.3 (6.5) | 6.0 (6.7) | 5.5 (4.9) | <.001 |
| Sex | |||||
| Women | 58 (45.3) | 78 (50.3) | 12 (57.1) | 342 (38.5) | .015 |
| Men | 70 (54.7) | 77 (49.7) | 9 (42.9) | 547 (61.5) | |
| Cohort | |||||
| MSBI (n = 307) | 55 (43.0) | 56 (36.1) | 6 (28.6) | 190 (20.9) | NA |
| HBS (n = 66) | 26 (20.3) | 0 | 0 | 40 (4.4) | NA |
| PDBP (n = 417) | 27 (21.1) | 0 | 1 (4.8) | 389 (42.8) | NA |
| LCC (n = 394) | 20 (15.6) | 99 (63.9) | 5 (23.8) | 290 (31.9) | NA |
| PPMI (n = 7) | 0 | 0 | 7 (33.3) | 0 | NA |
| SPOT (n = 2) | 0 | 0 | 2 (9.5) | 0 | NA |
| Levodopa equivalent dose | 692.7 (551.1) | 747.4 (545.1) | 283.3 (262.2) | 580.7 (489.7) | <.001f |
| MDS-UPDRS IIIc | 26.4 (13.6) | 24.7 (14.2) | 26.1 (9.1) | 24.5 (13.5) | .680 |
| MoCAc | 24.8 (4.8) | 25.4 (3.1) | 25.7 (2.6) | 25.5 (3.6) | .383 |
Abbreviations: HBS, Harvard Biomarkers Study; LCC, LRRK2 Cohort Consortium; MDS-UPDRS III, Movement Disorder Society–sponsored revision of the Unified Parkinson Disease Rating Scale, part III; MoCA, Montreal Cognitive Assessment; MSBI, Mount Sinai Beth Israel; NA, not applicable; PD, Parkinson disease; PDBP, Parkinson Disease Biomarker Program; PPMI, Parkinson disease Progression Marker Initiative.
P values correspond to test for equality among all groups.
Age at PD determined using age at onset when available and age at diagnoses otherwise.
Participant data was selected for inclusion if there was a complete motor rating (MDS-UPDRS III) or a cognitive task (MoCA) at any visit during their participation and demographic information (sex, age, and age at PD onset) available.